EP Patent

EP3937943A4 — NEW SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS

Assigned to General Hospital Corp · Expires 2022-12-07 · 3y expired

What this patent protects

Patent listed against Inrebic.

Drugs covered by this patent

Patent Metadata

Patent number
EP3937943A4
Jurisdiction
EP
Classification
—
Expires
2022-12-07
Drug substance claim
No
Drug product claim
No
Assignee
General Hospital Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.